相关实验视频
Updated: Jan 7, 2026

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
751
对于阿尔茨海默病的诊断和治疗的进展
Alexander Sunderland1, Alexandra Louise Thatcher1, Emily Victoria Rackley1
1Gloucestershire Health and Care NHS Foundation Trust, Gloucester, UK.
British journal of hospital medicine (London, England : 2005)
|December 24, 2025
概括
早期的阿尔茨海默病早期的阿尔茨海默病.
科学领域:
- 神经学 神经学
- 老年病的医生 老年病的医生
- 药理学 药理学是指药理学的学科.
背景情况:
- 随着人口老龄化,阿尔茨海默病 (AD) 的患病率正在增加.
- 早期诊断和疾病修改对于管理AD至关重要.
- 目前的AD管理需要更新一般医院的临床医生.
研究的目的:
- 审查最近在阿尔茨海默病诊断方面的进展.
- 综合阿尔茨海默病治疗的关键进展.
- 为临床医生提供关于管理AD的概述.
主要方法:
- 对阿尔茨海默病的诊断和治疗策略的文献综述.
- 分析神经成像,脑脊液和基于血的生物标志物检测.
- 对粉样蛋白向疾病修饰疗法的评估.
主要成果:
- 改善了粉样蛋白β (Aβ) 和化 (p-tau) 生物标志物的检测.
- 疾病修饰疗法如Lecanemab和Donanemab的出现.
- 认可神经炎症和氧化应激作为治疗点.
结论:
- 诊断和治疗方面的进步正在改变早期AD的识别和管理.
- 新疗法需要对ARIA等风险进行仔细的临床监测.
- 对AD病理生理学的全面理解指导着未来的治疗开发.
更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.7K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
27.9K
相关概念视频
Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Dementia
482
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
482
Parkinson's Disease: Treatment
933
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
933
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K